{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-016575","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2021-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.885963+00:00","generated_at":"2026-06-28T03:12:50.989277+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved","bullets":["6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.","One participant maintained maximal symptom improvement score of 7 at 24 months post-treatment.","AAV-hAQP1 well tolerated with no dose-limiting toxicities or serious adverse events reported.","Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in H2 2022.","Target market: ~170,000 US patients with grade 2/3 RIX; no new treatments approved in >20 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-016575","json":"https://secwatch.observer/filing/0001558370-21-016575.json","markdown":"https://secwatch.observer/filing/0001558370-21-016575.md","text":"https://secwatch.observer/filing/0001558370-21-016575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/0001558370-21-016575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/mgtx-20211207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:12:50.989277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}